About this Research Topic
Modern Radiotherapy (RT) plays a key role in the management of Head and Neck Cancer (HNC). More precise delivery techniques, advanced image-guidance, and adaptive treatments characterize modern RT, enabling safer treatments with enhanced therapeutic window.
Although patients identify the cure as their most important treatment outcome, complications related to treatment are a recognized problem as follow-up increases among those cured within this oncologic setting. This is particularly relevant for HPV-related oropharyngeal cancer (OPSCC), as these patients are younger, healthier, and more reactive to treatment. Thus, given the longer life expectancy, the jeopardizing impact of side effects on quality of life (QoL) and psychosocial functioning represent a forefront topic for HNC Researchers. De-escalation protocols have been developed recently, and, although not definitive, evidence is growing. This pertains particularly, but not exclusively, to HPV-related OPSCC.
Along with RT modernization in delivery and doses, its combinations with novel systemic agents and the clinical indications in the recurrent/metastatic (R/M) setting are certainly under the spotlight.
This Research Topic aims to present further evidence of the modern RT benefits in the HNC scenario. For this Research Topic, we welcome basic translational and clinical research papers, cancer biomarkers, professional opinions, and reviews in the broad field of radiotherapy for head and neck cancer in the following categories:
- De-escalated RT;
- Adaptive RT;
- Sparing Techniques;
- SBRT/SABR;
- Radiomics and radiotherapy;
- Reirradiation;
- Preclinical and radiobiology research;
- Combined modality treatments;
- Elderly patients.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Although patients identify the cure as their most important treatment outcome, complications related to treatment are a recognized problem as follow-up increases among those cured within this oncologic setting. This is particularly relevant for HPV-related oropharyngeal cancer (OPSCC), as these patients are younger, healthier, and more reactive to treatment. Thus, given the longer life expectancy, the jeopardizing impact of side effects on quality of life (QoL) and psychosocial functioning represent a forefront topic for HNC Researchers. De-escalation protocols have been developed recently, and, although not definitive, evidence is growing. This pertains particularly, but not exclusively, to HPV-related OPSCC.
Along with RT modernization in delivery and doses, its combinations with novel systemic agents and the clinical indications in the recurrent/metastatic (R/M) setting are certainly under the spotlight.
This Research Topic aims to present further evidence of the modern RT benefits in the HNC scenario. For this Research Topic, we welcome basic translational and clinical research papers, cancer biomarkers, professional opinions, and reviews in the broad field of radiotherapy for head and neck cancer in the following categories:
- De-escalated RT;
- Adaptive RT;
- Sparing Techniques;
- SBRT/SABR;
- Radiomics and radiotherapy;
- Reirradiation;
- Preclinical and radiobiology research;
- Combined modality treatments;
- Elderly patients.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Keywords: odern RT, Radiotherapy, IMRT, VMAT, IMPT, Head&Neck cancer, HNC, De-escalation, Adaptive RT, SBRT, SABR, Immunotherapy, Oropharynx, Nasopharynx, Larynx
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
